Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

NCT03242642 · View on ClinicalTrials.gov ↗

Study Summary

Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.

Conditions Studied

Interventions

  • DEVICE Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)

Study Locations (20)

California

  • Scripps Memorial Hospital — La Jolla
  • PIH Health Good Samaritan Hospital — Los Angeles
  • Kaiser Permanente Los Angeles Medical Center — Los Angeles
  • Keck Hospital of the University of Southern California, USC — Los Angeles
  • Cedars Sinai Medical Center — Los Angeles
  • El Camino Hospital — Mountain View
  • Kaiser Permanente San Francisco Medical Center — San Francisco
  • Stanford Hospital and Clinics — Stanford
  • Los Robles Regional Medical Center — Thousand Oaks

Florida

  • JFK Medical Center — Atlantis
  • Morton Plant — Clearwater
  • HealthPark Medical Center — Fort Myers
  • North Florida Regional Medical Center — Gainesville
  • Baptist Medical Center Jacksonville — Jacksonville
  • University of South Florida — Tampa

Connecticut

  • Hartford Hospital — Hartford
  • Yale New Haven Hospital — New Haven

Alabama

  • University of Alabama Birmingham (UAB) Hospital — Birmingham

Arizona

  • Abrazo Heart Hospital — Phoenix

District of Columbia

  • MedStar Washington Hospital Center — Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,056 participants
Start Date 2017-10-23
Est. Completion 2036-09-30
Phase NA

Sponsor

Medtronic Cardiovascular

49 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03242642

The ClinicalTrials.gov registry entry for NCT03242642 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 49 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Mitral Valve Regurgitation appearing as the primary indexed condition, and to 1 intervention — of which Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03242642 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03242642 about?

NCT03242642 is a clinical study titled "Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.". Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.

What is the current status of trial NCT03242642?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,056 participants. The study started on 2017-10-23. Estimated completion is 2036-09-30.

What conditions does trial NCT03242642 study?

This clinical trial studies the following conditions: Mitral Valve Regurgitation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03242642?

The interventions under investigation include: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03242642?

This trial is sponsored by Medtronic Cardiovascular, which has 49 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03242642 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial